Ajooni Biotech Approves Re-appointment of Director Gursimran Singh
Ajooni Biotech Limited has confirmed that its members approved the re-appointment of Mr. Gursimran Singh as a director during the company's 16th Annual General Meeting. The approval was passed via an ordinary resolution at the meeting held on Wednesday, July 29, 2026.The voting results and scrutiny report for the 16th Annual General Meeting were declared on July 31, 2026. This meeting, which was conducted through video conferencing, addressed the re-appointment of Mr. Gursimran Singh, who retires by rotation under Section 152(6) of the Companies Act, 2013.
Mr. Gursimran Singh is qualified as Bachelor of Commerce (B.Com) and holds a Master in Business Administration (MBA). He brings over 15 years of experience to the company, focusing on animal husbandry, crop cultivation, and supplements required for livestock. For eight years, he has served as CEO of Ajooni Biotech Limited.
The company confirmed that Mr. Gursimran Singh is not related to any Director or Key Managerial Personnel (KMP). Furthermore, reports confirm that he is not debarred from holding the office of a Director by any SEBI order or other similar authority.
Key details regarding the re-appointment and profile of the director are provided below:
| Detail | Information |
|---|---|
| Role | Appointment/Re-appointment (Director liable to retire by rotation) |
| Date of Appointment | Appointed effective July 29, 2026 |
| Brief Profile | Qualified with B.Com and MBA. Has over 15 years of experience in animal husbandry, crop cultivation, and livestock supplements. Has served as CEO of Ajooni Biotech Limited for the past eight years. |
| Director Relationship Disclosure | Mr. Gursimran Singh is not related to any Director or KMP of the company. |
| Debarment Status (NSE) | Not debarred from holding the office of Director by any SEBI order or other such authority. |
AJOONI Stock Price Movement
Ajooni Biotech Limited shares shed 0.5% today, settling at ₹4.00 as the market concluded trading. The company's equity was traded a volume of 97,601 shares during the post-market session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.